Institutions / Acorn Capital Advisors, LLC
Acorn Capital Advisors, LLC
CIK 2054410 · Institution · as of Dec 31, 2025
Portfolio value
$295.13M
Positions
21
As of
Dec 31, 2025
Top holdings
Dec 31, 2025
| Company | Value | % of portfolio |
|---|---|---|
| Terns Pharmaceuticals, Inc. | $70.55M | 23.9% |
| CG Oncology, Inc. | $46.98M | 15.9% |
| Urogen Pharma Ltd | $33.92M | 11.5% |
| Trevi Therapeutics, Inc. | $26.85M | 9.1% |
| Puma Biotechnology, Inc. | $24.58M | 8.3% |
| Candel Therapeutics, Inc.CADL | $14.58M | 4.9% |
| Cybin Inc. | $12.87M | 4.4% |
| Verastem, Inc. | $11.34M | 3.8% |
| Bicara Therapeutics Inc. | $10.83M | 3.7% |
| Protara Therapeutics, Inc. | $9.34M | 3.2% |
| OnKure Therapeutics, Inc. | $8.24M | 2.8% |
| Cardiff Oncology, Inc. | $5.51M | 1.9% |
| LeonaBio, Inc.LONA | $3.80M | 1.3% |
| Jasper Therapeutics IncJSPR | $3.27M | 1.1% |
| Aura Biosciences, Inc.AURA | $3.25M | 1.1% |
| Whitehawk Therapeutics, Inc.WHWK | $2.76M | 0.9% |
| Bioatla Inc | $2.76M | 0.9% |
| Q32 Bio Inc. | $1.64M | 0.6% |
| X4 Pharmaceuticals Inc | $1.09M | 0.4% |
| Acrivon Therapeutics, Inc.ACRV | $976.6K | 0.3% |
| Vyne Therapeutics Inc | $827 | 0.0% |
Activity
Dec 31, 2025
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.No quarter-over-quarter changes yet — position changes appear once we've ingested two consecutive 13F filings for this manager. We currently hold 1 quarter of holdings.